Oxford Ovarian Cancer Predict Chemotherapy Response 01

Advanced Ovarian Cancer and Sexuality Phase 1

NCT00488202 ·Status: COMPLETED

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

NCT01220154 ·Status: COMPLETED ·Phase: PHASE1

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00023907 ·Status: TERMINATED ·Phase: PHASE2

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01468909 ·Status: COMPLETED ·Phase: PHASE2

Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer

NCT00002894 ·Status: COMPLETED ·Phase: PHASE3

Patient Reported Symptoms in Ovarian Cancer (PRECISION)

NCT01422265 ·Status: COMPLETED

Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT00075543 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients

NCT03019315 ·Status: UNKNOWN

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003385 ·Status: COMPLETED ·Phase: PHASE1

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

NCT01048814 ·Status: COMPLETED

Search for Predictors of Therapeutic Response in Ovarian Carcinoma

NCT01391351 ·Status: COMPLETED ·Phase: NA

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02389985 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

NCT03117933 ·Status: COMPLETED ·Phase: PHASE2

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

NCT00005836 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT00003449 ·Status: COMPLETED ·Phase: PHASE2

The Treatment Preferences of Women Diagnosed With Ovarian Cancer

NCT03367260 ·Status: COMPLETED

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

NCT00060359 ·Status: COMPLETED ·Phase: PHASE1

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

NCT04608409 ·Status: COMPLETED ·Phase: PHASE1

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00897806 ·Status: TERMINATED

Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

NCT02399592 ·Status: COMPLETED ·Phase: PHASE2

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293 ·Status: COMPLETED ·Phase: PHASE1

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

NCT00170664 ·Status: COMPLETED ·Phase: PHASE2

Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom

NCT00757263 ·Status: UNKNOWN

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

NCT00102622 ·Status: TERMINATED ·Phase: PHASE1

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

NCT00183794 ·Status: COMPLETED ·Phase: PHASE2